Can You Expedite Vascepa's FDA Application Processing?
Vascepa (icosapent ethyl) received FDA approval in 2012 for triglyceride reduction and in 2020 for cardiovascular risk reduction via the EVAPORATE and REDUCE-IT trials.[1] Its original New Drug Application (NDA) processing completed without noted delays, but expedited pathways existed and could apply to similar lipid-lowering drugs today.
What Expedited FDA Programs Were Available for Vascepa?
The FDA offers priority review (6 months vs. 10 standard), fast track, accelerated approval, and breakthrough therapy designation for drugs addressing unmet needs like severe hypertriglyceridemia.[2] Vascepa qualified for fast track in 2009 due to its potential in high-risk patients unresponsive to statins, shortening early development interactions.[1][3] Sponsors request these via formal applications post-IND filing.
How Do You Request Expedited Review Today?
For a Vascepa-like NDA resubmission or new indication, submit a request with evidence of serious condition treatment, no alternatives, and preliminary efficacy data. FDA decides within 60 days.[2] Amarin Pharma used this for the 2020 label expansion, gaining priority review confirmed in November 2019.[1]
When Did Vascepa Get Priority Review Status?
Priority review granted for the cardiovascular outcome NDA (NDA 214883) in 2019, cutting review to 6 months and approving December 2020.[1][4] Standard review applied to the initial 2012 approval (NDA 202057).[3]
What Limits Expedited Processing for Supplements or Generics?
Vascepa faces ANDA challenges for generics, with no expedited generic pathway beyond standard 10-month review unless Paragraph IV litigation triggers 180-day exclusivity.[5] Patents expire 2039, blocking generics absent invalidation.[6]
Why Might Expedited Status Get Denied?
Denials occur without surrogate endpoint data, confirmatory trial plans, or unmet need proof. Vascepa's REDUCE-IT success supported its grant; weaker data risks rejection.[2]
[1]: FDA Approval History for Vascepa
[2]: FDA Expedited Programs
[3]: Drugs@FDA - Vascepa
[4]: Amarin Press Release on Priority Review
[5]: FDA Generic Drug Review Process
[6]: DrugPatentWatch - Vascepa Patents